Beta-Endorphin
A 31-amino acid endogenous opioid peptide produced in the pituitary and hypothalamus - the primary mediator of exercise-induced euphoria, stress analgesia, and immune modulation.
Community Rating
No ratings yet
⚠ Research & Educational Use Only. Beta-Endorphin is a research chemical documented here for scientific education. All information references peer-reviewed literature and preclinical/clinical study data. Not for human consumption. Not medical advice. Consult a licensed researcher or healthcare professional before any laboratory use.
- Most potent endogenous analgesic: mu-opioid receptor activation produces analgesia 18-33x more potent than morphine on a molar basis
- Mediates the 'runner's high' - exercise-induced euphoria documented by PET imaging showing mu-opioid receptor occupancy
- Regulates stress responses: released alongside ACTH under stress to modulate pain and mood
- Beta-Endorphin is not FDA-approved for human use. It is a research chemical for scientific study only.
Research At a Glance
- Most potent endogenous analgesic: mu-opioid receptor activation produces analgesia 18-33x more potent than morphine on a molar basis
- Mediates the 'runner's high' - exercise-induced euphoria documented by PET imaging showing mu-opioid receptor occupancy
- Regulates stress responses: released alongside ACTH under stress to modulate pain and mood
- Immunomodulatory: activates natural killer cells, T lymphocytes, and monocytes via peripheral opioid receptors
What is Beta-Endorphin?
Tap any underlined term for an instant definition.
Beta-endorphin is a 31-amino acid endogenous opioid peptide derived by post-translational processing of the precursor protein proopiomelanocortin (POMC) in the anterior and intermediate lobes of the pituitary gland, and in neurons of the hypothalamic arcuate nucleus that project throughout the brain and spinal cord. The name derives from "endogenous morphine" - coined when the endogenous ligands for opioid receptors were first identified in 1975, in a discovery that explained why plant-derived opiates (morphine, codeine) were pharmacologically active in mammalian tissues - they were mimicking molecules the body itself produces.
Beta-endorphin is one of three families of endogenous opioid peptides (the others being the enkephalins and dynorphins) and is the primary endogenous agonist at the mu-opioid receptor (MOR). On a molar basis, beta-endorphin is approximately 18-33x more potent than morphine at MOR, making it the most potent analgesic molecule produced endogenously. The high potency and selectivity of beta-endorphin for MOR, combined with its hypothalamic and pituitary origins, position it as a major neuromodulator of pain, stress, mood, and reproductive physiology.
The co-regulation of beta-endorphin and ACTH (adrenocorticotropic hormone) from the same POMC precursor ensures their simultaneous release during stress. When the hypothalamo-pituitary-adrenal (HPA) axis is activated - by pain, psychological stress, exercise, or illness - CRH stimulates corticotroph cells to cleave POMC into ACTH (which drives cortisol release) and beta-endorphin (which produces analgesia and mood elevation). This coordinated release makes biological sense: the capacity to tolerate pain is enhanced precisely when the animal is under attack or exertion.
The "runner's high" represents the most socially prominent manifestation of beta-endorphin biology. The phenomenon - characterised by euphoria, reduced pain sensitivity, and emotional well-being during and after sustained aerobic exercise - has been debated mechanistically for decades. The popular attribution to endorphins was long based on indirect evidence (naloxone blockade of exercise analgesia) and was complicated by the fact that plasma beta-endorphin levels rise during exercise but the peptide crosses the blood-brain barrier poorly. In 2008, Boecker and colleagues used PET imaging with a mu-opioid receptor ligand to directly demonstrate increased opioid receptor occupancy in the frontal and limbic regions of marathon runners' brains after a long run, with the degree of opioid binding correlating with subjective euphoria ratings. This provided the first direct evidence that exercise-induced endorphin release in the brain mediates the affective components of the runner's high.
The immune-modulatory properties of beta-endorphin are mediated through opioid receptors expressed on natural killer cells, T and B lymphocytes, macrophages, and dendritic cells. Beta-endorphin stimulates natural killer cell cytotoxicity, enhances T-cell proliferation, and modulates cytokine production. These immune effects appear to provide a link between psychological states and immune function - explaining, for example, why acupuncture (which elevates brain endorphin levels, as documented by PET) may have immune-modulatory effects and why psychological stress (which acutely elevates then depletes endorphins) affects immune function.
The endogenous opioid system's role in social bonding has emerged as an important area of neuroscience research. The "social pain" hypothesis - supported by imaging and pharmacological studies - proposes that social exclusion and rejection activate some of the same neural circuits as physical pain, and that endogenous opioids buffer against social distress. Studies using naltrexone (opioid receptor blocker) have shown that opioid blockade reduces social warmth and increases loneliness in healthy humans. Conversely, positive social interactions, laughter, and physical touch elevate endorphin levels as measured by PET opioid receptor occupancy studies, suggesting the endorphin system mediates the reinforcing and stress-buffering qualities of social affiliation.
Key Research Benefits
Documented effects observed in preclinical and clinical studies on Beta-Endorphin. See all Cognitive Enhancement peptides for comparison.
Side Effects & Risks
Adverse effects reported in the research literature. All data sourced from preclinical and clinical study reports. View all peptides' side effects →
Dosing Data from the Literature
Doses referenced below are sourced from published preclinical and clinical studies. Use the peptide dose calculator to convert these values to injection volume.
Beta-endorphin is used primarily as a research tool rather than a therapeutic agent:
IV/ICV research administration: - Pain and analgesia research: 0.1-10 nmol intracerebroventricularly in rodent models - Immune function research: 10-100 ng/mL in cell culture assays - Neuroendocrine research: 0.01-1 nmol ICV for GnRH/GHRH modulation studies
Induction of endogenous beta-endorphin release (research): - High-intensity exercise (>70% VO2max) for 30+ minutes reliably elevates plasma beta-endorphin 2-5 fold - Electrical acupuncture stimulation produces measurable CNS beta-endorphin release (PET-documented) - Social laughter and positive social interaction - documented to elevate beta-endorphin via PET
Administration in Research Settings
Standard reconstitution and administration methodology for laboratory research use.
Research applications only - not intended for direct clinical administration. Used in: - Receptor binding assays: radiolabelled ([125I]-beta-endorphin) for opioid receptor characterisation - Electrophysiology: bath application to neuronal preparations to study opioid-sensitive currents - ICV delivery in rodents: via stereotaxically implanted cannula for dose-response studies - Cell biology: added to culture media for immune cell activation assays
Research Video
Explore Further
Quick Reference
Research Use Only
This information is for educational research purposes only. This is not medical advice. Consult a qualified healthcare professional.
